Premier Alternatives

Resonant Therapeutics

Houston, TX · Founded 2014 · Privately Held (backing)

Developer of a drug discovery platform designed to help pharma clients expand their drug discovery pipeline. Resonant Therapeutics is based in Houston, TX and was founded in 2014. It is valued at about $17.3 million as of Oct 2026, set by institutional fund marks. It has raised $6.1 million across 1 recorded round; the latest was a $2.5 million seed round in Oct 2021.

PMV mark · valuation
$17.3M
Oct 2026
Priced at
its later-stage round
Oct 2021
Total raised
$6.1M
Last round
Seed Round
Oct 2021

Resonant Therapeutics key facts

as of Oct 2026
  • Developer of a drug discovery platform designed to help pharma clients expand their drug discovery pipeline.
  • Resonant Therapeutics is valued at approximately $17.3M as of Oct 2026, per PrivateMarketView’s mark.
  • It has raised $6.1M across 1 recorded rounds; the latest was Seed Round ($2.5M) in Oct 2021.
  • Notable investors include Johnson & Johnson Innovation - JLABS, Mercury Fund, Innovation Partnerships, Urban Capital Network, MINTS (Michigan Investment in New Technology Startups) — 7 tracked in total.
  • 1 institutional filer reports fund marks on Resonant Therapeutics across 9 filings.
  • Resonant Therapeutics has filed 1 Form D with the SEC, most recently Oct 2021 ($2.5M sold to 16 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$17.3M

Nothing comparable since the round — shown at its later-stage round, Oct 2021 ($17.3M post-money).

set by institutional fund marksas of Oct 2026question about this number?
Free account
More of Resonant Therapeutics with a free account
  • ·Watch Resonant Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Institutional fund marks on Resonant Therapeutics

1 filers · latest Jul 2026

1 SEC-registered fund reported 9 fair-value marks on Resonant Therapeutics between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 9 fund marks

Membership and data by Private Market View

Every name the funds mark, next to where it trades →

Resonant Therapeutics funding rounds

1 rounds
Oct 2021Seed Round$2.5MSEC filing▮
Full funding history →

Resonant Therapeutics valuation

Resonant Therapeutics is valued at approximately $17.3 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Oct 2021, at a $17.3 million post-money valuation.

Recent activity

In the last 90 days, Resonant Therapeutics's record added 3 institutional fund marks (latest period Jul 2026).

How much has Resonant Therapeutics raised?

Resonant Therapeutics has raised $6.1 million in total; 1 of its rounds is on record. The largest on record was a $2.5 million seed round in Oct 2021.

Resonant Therapeutics has filed 1 Form D with the SEC, most recently in Oct 2021 ($2.5 million sold to 16 investors).

Institutional holders and vehicles

1 SEC-registered fund reported 9 fair-value marks on Resonant Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

Resonant Therapeutics investors

7 investors are on record for Resonant Therapeutics, including Johnson & Johnson Innovation - JLABS, Mercury Fund, Innovation Partnerships and Urban Capital Network. The seed round in Oct 2021 drew 16 investors.

About Resonant Therapeutics

Developer of a drug discovery platform designed to help pharma clients expand their drug discovery pipeline. The company's platform focuses on the tumour microenvironment and data science to identify novel tumour-selective targets and anti-tumour antibodies, enabling researchers to identify and accelerate therapeutic and target discovery against cancers.

Sector
Healthcare
HQ
Houston, TX, United States
Founded
2014
Employees
5
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.